EMA Confirms Suicidal Thoughts with Finasteride — Detailed summary, implications, and a practical pharmacovigilance / manufacturer action plan
Source documents: EMA PRAC communications and referral page (May–June 2025). European Medicines Agency (EMA)+1 Executive summary — the one-minute version What PRAC found (evidence & conclusions) Key regulatory changes and public health measures Clinical and public-health implications (who should worry and what to do) Impact on manufacturers — regulatory & operational checklist Manufacturers (brand and […]
EMA’s Update on Azithromycin Use — May 23, 2025
Key Regulatory Shift The European Medicines Agency’s (EMA) CHMP recommended updating the approved uses of azithromycin (oral and IV) to combat rising antimicrobial resistance (AMR)—particularly given its designation in WHO’s Watch category, which flags antibiotics at higher risk of driving resistance. (turn0search0) What’s Changed? Refined and Harmonized Indications Approvals have been narrowed and standardized, covering […]
Deep brief — Formal Meetings Between FDA and Sponsors/Applicants of BsUFA Products
Guidance for Industry (CDER & CBER, July 2025) — what it says, why it matters, and exactly what regulatory, pharmacovigilance (PV), quality, clinical and commercial teams must do day-to-day. U.S. Food and Drug Administration Quick summary (the headline) This FDA guidance codifies how sponsors of biosimilar or interchangeable biologic products should request, prepare for, run, […]
Deep Brief — Medical Device User Fee Small Business Qualification & Determination (FDA guidance, July 31, 2025)
What it is, why it matters, and exactly what manufacturers — including regulatory, PV/PS (pharmacovigilance / product safety), quality and finance teams — must do Short version: This FDA guidance explains how device and biologics firms can qualify as a “small business” for reduced MDUFA user fees (and for a one-time waiver of a first […]
Philips Respironics BiPAP A30 / A40 / V30 — Continuous Ventilator Correction, Clinical Risks, and Manufacturer Action Plan
Source: FDA Medical Device Recalls page (updated Aug 6, 2025).Link reviewed: FDA recall notice for Philips Respironics update of use instructions for BiPAP A30, A40, and V30 due to interruptions and/or loss of therapy. U.S. Food and Drug Administration Executive summary Philips Respironics issued an urgent device correction for all lots of the BiPAP A30, […]
Early Alert: Boston Scientific ENDOTAK RELIANCE Defibrillation Leads — investigative report, clinical guidance, and manufacturer action plan
Source: FDA Early Alert (posted Aug 6, 2025). U.S. Food and Drug Administration Executive summary (two sentences) The FDA posted an Early Alert after Boston Scientific notified clinicians that certain ENDOTAK RELIANCE defibrillation leads with ePTFE-coated shock coils are showing coil calcification that correlates with a gradual rise in low-voltage shock impedance (LVSI) and can […]
Early Alert: Medline ReNewal Reprocessed EP Catheters with Residual Particulates – What You Need to Know
Date of FDA Page Update: August 6, 2025 U.S. Food and Drug Administration The device and product details These catheters are used for electrophysiology (EP) mapping, stimulation, and recording in diagnosing and managing cardiac arrhythmias via endocardial and intravascular access. U.S. Food and Drug Administration Reason for the Early Alert Medline ReNewal found that affected […]
Max Mobility / Permobil Expands Worldwide Recall of SmartDrive SpeedControl Dial — Investigative report and manufacturer action plan
Published: August 12, 2025Source: Company announcement posted on FDA recalls page. U.S. Food and Drug Administration Executive summary (quick take) Max Mobility / Permobil has announced a voluntary, worldwide expanded recall and market removal of all SpeedControl Dials used with the SmartDrive MX2+ power-assist device. The action covers every SpeedControl Dial manufactured and distributed between […]
FDA & CDC Recommend Pause of IXCHIQ (Chikungunya Vaccine, Live) for Adults 60+ — An Investigative Update
Published: May 12, 2025 (FDA safety communication).Quick summary: The FDA and CDC have recommended a temporary pause in the use of IXCHIQ® (Chikungunya Vaccine, Live) for people 60 years and older while agencies investigate postmarketing reports of serious neurologic and cardiac events, including deaths. This article explains what’s known, what the agencies are doing, who’s […]